Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

3.515 -0.075 (-2.09%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Here's Why You Should Avoid CureVac Stock Like the Plague
Funds will not be safe if invested in this coronavirus stock. 
Via The Motley Fool
Exposures COVID-19
Is CureVac a Bargain Bet on mRNA Vaccine Technology?
CureVac shares have slipped more than 20% on bad news. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
Why CureVac Shares Are Trading Lower Today
CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% ... 
Via Benzinga
CVAC Stock Price Increases 14%: Why It Happened
CureVac BV (NASDAQ:CVAC) shares are trading higher by 14% ... 
Via Benzinga
Moderna and Pfizer May Benefit From This Rival's Bad News
And it could equal billions of dollars for these vaccine leaders. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Can CureVac Recover After Its Vaccine Setback?
Investors' dreams of a third strong mRNA vaccine may be over. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
30 Stocks Moving In Thursday's Mid-Day Session
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on Wednesday after the company priced its IPO at $6 per... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Analyzing CureVac's Unusual Options Activity
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Thursday. The stock price moved down to $68.53 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
Via Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
A Peek Into The Markets: US Stock Futures Up Ahead Of Initial Jobless Claims Data
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of initial jobless claims data. The Dow Jones climbed over 200 points on Wednesday, while the S... 
Via Benzinga
Topics Stocks
Exposures US Equities
CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails Rivals
The German biotech company CureVac BV (NASDAQ: CVAC) announced on Wednesday after hours the final results of its late-stage COVID-19 vaccine trial showing 48%... 
Via Benzinga
Exposures COVID-19
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
- Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent - Statistical... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 30, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
June’s Best and Worst Performing Russell 1,000 Stocks
The month of June, the second quarter and the first half of 2021 are almost in the bag. 
Via Talk Markets
Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?
Things are looking bleak right now, but they might improve with enough time. 
Via The Motley Fool
Exposures COVID-19
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY andBOSTON, MA / ACCESSWIRE / June 25, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac Provides Supervisory Board Update
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 23, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Could CureVac Be a Millionaire-Maker Stock?
CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising. 
Via The Motley Fool
Exposures COVID-19
How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges
Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna. 
Via The Motley Fool
Exposures COVID-19
Europe Purchases Additional 150M Doses Of Moderna COVID-19 Vaccine
The European Union has decided to take up an option under a supply contract with Moderna Inc (NASDAQ: MRNA) that allows the bloc to order 150 million... 
Via Benzinga
Exposures COVID-19
Why Is Everyone Talking About CureVac Stock?
This coronavirus vaccine developer just hit a massive stumbling block. 
Via The Motley Fool
Exposures COVID-19
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
58 Biggest Movers From Friday
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
Stock Market Rally Shifts To Tech After Fed Meeting; Adobe, Ford In Focus: Weekly Review
Techs seized stock market leadership, despite the Fed signaling earlier rate hikes. But many real economy names dived. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Economy Fossil Fuels Interest Rates
32 Stocks Moving In Friday's Mid-Day Session
Gainers CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Sykes Enterprises,... 
Via Benzinga
28 Stocks Moving in Friday's Pre-Market Session
Gainers CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Geron... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.